ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) CEO Richard Lowenthal sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $15.03, for a total value of $1,503,000.00. Following the sale, the chief executive officer now owns 1,497,447 shares of the company’s stock, valued at $22,506,628.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
ARS Pharmaceuticals Trading Up 1.9 %
SPRY stock traded up $0.24 during midday trading on Monday, hitting $13.20. The stock had a trading volume of 876,687 shares, compared to its average volume of 715,928. The stock has a 50-day simple moving average of $10.43 and a 200 day simple moving average of $9.36. ARS Pharmaceuticals, Inc. has a 52 week low of $2.55 and a 52 week high of $16.50. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -24.92 and a beta of 0.87.
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $2.00 million. On average, equities analysts forecast that ARS Pharmaceuticals, Inc. will post -0.66 EPS for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
SPRY has been the subject of a number of analyst reports. Cantor Fitzgerald began coverage on ARS Pharmaceuticals in a research report on Tuesday, August 20th. They set an “overweight” rating and a $30.00 price objective for the company. Leerink Partners upped their price target on shares of ARS Pharmaceuticals from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Monday, August 12th. Finally, Raymond James raised ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $18.00 to $22.00 in a research note on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $22.75.
Get Our Latest Analysis on SPRY
ARS Pharmaceuticals Company Profile
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
Featured Stories
- Five stocks we like better than ARS Pharmaceuticals
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Why the Buy-and-Hold Strategy May Be Best for Most Investors
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Eli Lilly’s Path to the Next Trillion Market Capitalization
- What is the NASDAQ Stock Exchange?
- Mobileye Global: CEO Makes $10 Million Bet on Future Strength
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.